Development of tumor-targeted nanodelivery systems for novel inhibitors of ERCC1/XPF for chemo and radio-sensitization of solid tumors

开发用于实体瘤化疗和放射增敏的新型 ERCC1/XPF 抑制剂的肿瘤靶向纳米递送系统

• 批准号: 495239
• 负责人: Ahmed Ahmed
• 金额: $ 0.11万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-10-01 至 2024-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=495239&lang=en
• 关键词: Ics Travel Award

Head and neck cancer (HNC) ranks seventh globally, with over 660,000 new cases, 325,000 deaths annually, and an estimated 30% rise by 2030. Nonsurgical treatments for HNC mainly include radiation therapy and platinum-based DNA damaging therapies. However,

头颈癌 (HNC) 在全球排名第七，每年新增病例超过 660,000 例，死亡人数为 325,000 人，预计到 2030 年将增加 30%。HNC 的非手术治疗主要包括放射治疗和铂类 DNA 损伤治疗。然而，